This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2010 Jan;37(1):1-2.

doi: 10.1007/s00259-009-1215-9.

Is (123)I-MIBG cardiac scintigraphy a surrogate marker for Parkinson's disease?

Hidenao Fukuyama

PMID: 19626323
DOI: 10.1007/s00259-009-1215-9

Editorial

Is (123)I-MIBG cardiac scintigraphy a surrogate marker for Parkinson's disease?

Hidenao Fukuyama. Eur J Nucl Med Mol Imaging. 2010 Jan.

. 2010 Jan;37(1):1-2.

doi: 10.1007/s00259-009-1215-9.

Author

Hidenao Fukuyama

PMID: 19626323
DOI: 10.1007/s00259-009-1215-9

No abstract available

PubMed Disclaimer

Comment on

Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET.
Ishibashi K, Saito Y, Murayama S, Kanemaru K, Oda K, Ishiwata K, Mizusawa H, Ishii K. Ishibashi K, et al. Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):3-11. doi: 10.1007/s00259-009-1202-1. Eur J Nucl Med Mol Imaging. 2010. PMID: 19626324

Similar articles

Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET.
Ishibashi K, Saito Y, Murayama S, Kanemaru K, Oda K, Ishiwata K, Mizusawa H, Ishii K. Ishibashi K, et al. Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):3-11. doi: 10.1007/s00259-009-1202-1. Eur J Nucl Med Mol Imaging. 2010. PMID: 19626324
(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease.
Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H. Orimo S, et al. J Neurol Neurosurg Psychiatry. 1999 Aug;67(2):189-94. doi: 10.1136/jnnp.67.2.189. J Neurol Neurosurg Psychiatry. 1999. PMID: 10406987 Free PMC article.
Thyroid MIBG uptake in Parkinson's disease with diabetes mellitus.
Jang W, Kim JS, Cho JW, Ahn JY, Choi YY, Kim HT. Jang W, et al. Clin Auton Res. 2013 Aug;23(4):221-4. doi: 10.1007/s10286-013-0204-z. Epub 2013 Jul 11. Clin Auton Res. 2013. PMID: 23843160
Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease.
Taki J, Yoshita M, Yamada M, Tonami N. Taki J, et al. Ann Nucl Med. 2004 Sep;18(6):453-61. doi: 10.1007/BF02984560. Ann Nucl Med. 2004. PMID: 15515743 Review.
123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders.
Rascol O, Schelosky L. Rascol O, et al. Mov Disord. 2009;24 Suppl 2:S732-41. doi: 10.1002/mds.22499. Mov Disord. 2009. PMID: 19877202 Review.

See all similar articles

Cited by

SPECT molecular imaging in Parkinson's disease.
Wang L, Zhang Q, Li H, Zhang H. Wang L, et al. J Biomed Biotechnol. 2012;2012:412486. doi: 10.1155/2012/412486. Epub 2012 Mar 24. J Biomed Biotechnol. 2012. PMID: 22529704 Free PMC article. Review.

References

1. Acta Neuropathol. 2007 Jan;113(1):81-6 - PubMed
1. Eur J Neurol. 2009 Feb;16(2):174-82 - PubMed
1. Eur J Nucl Med. 1988;14(7-8):341-4 - PubMed
1. Acta Neuropathol. 1978 May 24;42(2):127-34 - PubMed
1. Rinsho Shinkeigaku. 1993 Jul;33(7):784-6 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Medical
- MedlinePlus Health Information